• That could lead to a quandary for doctors who are already prescribing Thalomid for multiple myeloma.

    FORBES: Celgene Aims For Fast FDA Approval

  • Thalomid had been approved for leprosy the year before, but it very quickly became used mostly for myeloma.

    FORBES: Health Care

  • But just because she played a key role in Thalomid's development doesn't prove that Celgene owes her a dime.

    FORBES: Health Care

  • For instance, most use of Celgene 's (nadsaq: CELG - news - people ) Thalomid is off-label.

    FORBES: When Doctors Go Off-Label

  • Within the next six months Celgene will likely win approval to market both Thalomid and Revlimid as treatments for multiple myeloma.

    FORBES: Magazine Article

  • It took a median of 76 weeks for patients taking both Thalomid and dexamethasone, an existing chemotherapy, to see their diseases worsen.

    FORBES: Thalomid Fuels Celgene's Rise

  • Revlimid, Celgene's second biggest-selling drug, is basically an improved version of Thalomid.

    FORBES: Magazine Article

  • When it received approval to sell the drug as Thalomid, Warren, N.

    FORBES: Magazine Article

  • Revlimid is the chemical cousin and heir to Celgene's first drug, Thalomid, which is still probably better known by its generic name, thalidomide.

    FORBES: Inside Medicine

  • Celgene and Pharmion have been partners since 2001, when Pharmion began selling Thalomid in Europe and Celgene acquired an equity stake in the smaller company.

    FORBES: Celgene's Smart Buy

  • The new trial, which included 270 patients whose multiple myeloma was being treated for the first time, leaves little doubt about Thalomid's efficacy against the cancer.

    FORBES: Thalomid Fuels Celgene's Rise

  • Celgene 's (nasdaq: CELG - news - people ) Thalomid was approved to treat leprosy but is used mainly as a life-saving cancer medicine.

    FORBES: Silver Lining In Drug Disclosure

  • Richardson points out that Thalomid, Celgene's follow-up drug Revlimid and Velcade, from Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) of Cambridge, Mass.

    FORBES: Thalomid Fuels Celgene's Rise

  • It was her husband's doctor, Bart Barlogie of the University of Arkansas Medical Center, who ran the first clinical trial to show Thalomid's effect in multiple myeloma.

    FORBES: Health Care

  • In a tougher measure of efficacy that takes into account how long patients lived, called progression-free survival, Thalomid more than doubled the length of time patients lived, to 57 weeks.

    FORBES: Thalomid Fuels Celgene's Rise

  • "That's very impressive, " says Paul Richardson, a myeloma specialist at the Dana-Farber Cancer Institute who has worked on other Celgene-sponsored trials but did not participate in this Thalomid study.

    FORBES: Thalomid Fuels Celgene's Rise

  • So far, says Chief Scientific Officer David Stirling , Revimid does not cause such birth defects in New Zealand rabbits--the only animal model in which the Thalomid problem shows up.

    FORBES: Magazine Article

  • Thalomid is now widely used to treat multiple myeloma.

    FORBES: Magazine Article

  • However, Thalomid did have serious side effects.

    FORBES: Thalomid Fuels Celgene's Rise

  • Revlimid may not cause birth defects, but the FDA wants further data before freeing it from the tight restrictions that keep Thalomid from being used in women who are pregnant or who could become pregnant.

    FORBES: Thalomid Fuels Celgene's Rise

  • But though Thalomid is widely used by doctors to treat multiple myeloma based on preliminary data, it is approved by the U.S. Food and Drug Administration only to treat a skin condition associated with leprosy.

    FORBES: Thalomid Fuels Celgene's Rise

  • Revimid, in any case, was designed to be a more potent and safer version of Celgene's existing drug, Thalomid, which was linked to birth defects when used decades ago as an anti-nausea treatment during pregnancy.

    FORBES: Celgene Aims For Fast FDA Approval

  • Thalomid is also a big seller.

    FORBES: Thalomid Fuels Celgene's Rise

  • According to Li, there are two other VEGF-targeted drugs in late-stage clinical trials: Neovastat, developed by Aeterna Laboratories (nasdaq: AELA - news - people ), and Thalomid, better known as thalidomide, which is being tested by Celgene (nyse: CELG - news - people ).

    FORBES: Will Genentech's Failure Hurt Other Biotechs?

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定